# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

# FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2024

# ROCKET LAB USA, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-39560

(Commission File Number)

98-1550340 (IRS Employer Identification No.)

3881 McGowen Street
Long Beach, California
(Address of Principal Executive Offices)

90808 (Zip Code)

Registrant's Telephone Number, Including Area Code: 714 465-5737

# Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

ck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following visions:	
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	
Securities registered pursuant to Section 12(b) of the Act:	
Trading	
Title of each class Symbol(s) Name of each exchange on which registered	

Title of each class	Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	RKLB	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\Box$ 

## Item 2.02 Results of Operations and Financial Condition.

On November 12, 2024, Rocket Lab USA, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 (the "Section") of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Description
Press Release of Rocket Lab USA, Inc., dated November 12, 2024
Cover Page Interactive Data File (embedded within the Inline XBRL document).

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ROCKET LAB USA, INC.

Date: November 12, 2024 By: /s/ Adam Spice

Adam Spice

Chief Financial Officer



Exhibit 99.1

# Rocket Lab Announces Third Quarter 2024 Financial Results, Posts 55% Year-on-Year Growth and Guides to Record Revenue in Q4

**Long Beach, California. November 12, 2024** – Rocket Lab USA, Inc. ("Rocket Lab", "the Company", "we," "us," or "our"), a global leader in launch services and space systems, today shared the financial results for fiscal third quarter, ended September 30, 2024.

Rocket Lab founder and CEO, Sir Peter Beck, said: "In the third quarter 2024 we once again executed against our end-to-end space strategy with successes and key achievements reached across small and medium launch, as well as space systems. Revenue grew 55% year-on-year to \$105 million and we continue to see strong demand growth with our backlog at \$1.05 billion. Significant achievements for the quarter included signing a launch service agreement for multiple launches on Neutron with a confidential commercial satellite constellation customer; successfully launching twelve Electron launches year-to-date, making 2024 a record year for launches with more still to come; signing \$55 million in new Electron launches, further cementing Electron's position as a global launch leader; and being selected by NASA to complete a study contract for a proposal to retrieve samples from Mars and return them to Earth as part of a world-first mission. We expect to close out the year strongly with more Electron launches scheduled in November and December, alongside continued progress across Neutron and space systems, that is behind our guidance for a record \$125-\$135 million revenue quarter in Q4."

# Business Highlights for the Third Quarter 2024, plus updates since September 30, 2024. Electron:

- Achieved a new annual launch record of 12 Electron launches to date, with more scheduled across November and December 2024.
   Electron is the world's third most-frequently launched rocket annually by vehicle type and remains the United States' second most-frequently launched rocket annually.
- Signed several new Electron launch contracts in Q3 2024 with a total value of \$55m, demonstrating an increased average selling price of \$8.4m and showcasing a 67% pricing increase since the rocket's debut launch.
- Successful Electron launches for three separate commercial satellite constellation operators in Q3, including two missions launched within just eight days. In addition to these, Electron's most recent mission, launched in the fourth quarter on November 5th, 2024, included an expedited turnaround of just 10 weeks between contract signing and launch.

#### **Neutron:**

- Signed a launch service agreement for multiple launches on Neutron with a confidential commercial satellite constellation operator that signifies the beginning of a productive collaboration that could see Neutron deploy the entire constellation.
- Announced a federal defense contract that supports Neutron and the development of its Archimedes engine with the U.S. Air Force's Research Laboratory.
- Doubled engine testing cadence for Archimedes over the quarter at Rocket Lab's engine test site in Mississippi, alongside strong
  production execution at the Company's Engine Development Complex in California which included multiple engines manufactured,
  assembled, and shipped for engine testing.



- Significant progress made across Neutron's structures and infrastructure, including the completion of construction on the rocket's Assembly, Integration, and Test (A.I.T.) facility in Virginia.
- Well-positioned to on-ramp to the U.S. Space Force's National Security Space Launch (NSSL) Lane 1 program, which began accepting proposals in November 2024 to on-ramp new launch providers to an indefinite delivery indefinite quantity (IDIQ) contract valued at \$5.6 billion over a five-year period.

#### **Space Systems:**

- Completed production and delivery of two spacecraft on time and on budget for NASA's ESCAPADE mission to Mars.
- Selected by NASA to complete a study contract for a proposal to retrieve samples from Mars and return them to Earth, a first-ofits-kind mission.
- Completed two new spacecraft for Varda Space Industries to conduct the 2nd and 3rd missions to return in-space manufacturing capsules to Earth.
- Executed on schedule against the Company's \$515 million prime contract with the Space Development Agency to build 18 spacecraft for its Tranche 2 Transport Layer program.

#### Fourth Quarter 2024 Guidance

### For the fourth quarter of 2024, Rocket Lab expects:

- Revenue between \$125 million and \$135 million.
- GAAP Gross Margins between 26% and 28%.
- Non-GAAP Gross Margins between 32% and 34%.
- GAAP Operating Expenses between \$84 million and \$86 million.
- Non-GAAP Operating Expenses between \$75 million and \$77 million.
- Expected Interest Expense (Income), net \$1.5 million.
- Adjusted EBITDA loss of \$27 million and \$29 million.
- Basic Shares Outstanding of 501 million.

See "Use of Non-GAAP Financial Measures" below for an explanation of our use of Non-GAAP financial measures, and the reconciliation of historical Non-GAAP measures to the comparable GAAP measures in the tables attached to this press release. We have not provided a reconciliation for the forward-looking Non-GAAP Gross Margin, Non-GAAP Operating Expenses or Adjusted EBITDA expectations for Q4 2024 described above because, without unreasonable efforts, we are unable to predict with reasonable certainty the amount and timing of adjustments that are used to calculate these non-GAAP financial measures, particularly related to stock-based compensation and its related tax effects. Stock-based compensation is currently expected to range from \$12 million to \$14 million in Q4 2024.

#### **Conference Call Information**

Rocket Lab will host a conference call for investors at 2 p.m. PT (5 p.m. ET) today to discuss these business highlights and financial results for our third quarter, to provide our outlook for the fourth quarter, and other updates.

The live webcast and a replay of the webcast will be available on Rocket Lab's Investor Relations website: <a href="https://investors.rocketlabusa.com/events-and-presentations/events">https://investors.rocketlabusa.com/events-and-presentations/events</a>



#### **About Rocket Lab**

Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier, and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle, a family of spacecraft platforms, and the Company is developing the large Neutron launch vehicle for constellation deployment. Since its first orbital launch in January 2018, Rocket Lab's Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered 198 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab's spacecraft platforms have been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch pad in Virginia. To learn more, visit www.rocketlabusa.com.

+ Rocket Lab Investor Relations Contact

Adam Spice investors@rocketlabusa.com

+ Rocket Lab Media Contact Murielle Baker media@rocketlabusa.com



#### + FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our expectations of financial results for the fourth quarter of 2024, launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy are forward-looking statements. The words "believe," "may," "will," "estimate," "potential," "continue," "anticipate," "intend," "expect," "strategy," "future," "could," "would," "project," "plan," "target," and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the "SEC"), accessible on the SEC's website at www.sec.gov and the Investor Relations section of our website at www.rocketlabusa.com, which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.



#### + USE OF NON-GAAP FINANCIAL MEASURES

We supplement the reporting of our financial information determined under Generally Accepted Accounting Principles in the United States of America ("GAAP") with certain non-GAAP financial information. The non-GAAP financial information presented excludes certain significant items that may not be indicative of, or are unrelated to, results from our ongoing business operations. We believe that these non-GAAP measures provide investors with additional insight into the company's ongoing business performance. These non-GAAP measures should not be considered in isolation or as a substitute for the related GAAP measures, and other companies may define such measures differently. We encourage investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure. Reconciliation of the non-GAAP financial information to the corresponding GAAP measures for the historical periods disclosed are included at the end of the tables in this press release. We have not provided a reconciliation for forward-looking non-GAAP financial measures because, without unreasonable efforts, we are unable to predict with reasonable certainty the amount and timing of adjustments that are used to calculate these non-GAAP financial measures, particularly related to stock-based compensation and its related tax effects. The following definitions are provided:

#### + ADJUSTED EDITDA

EBITDA is defined as earnings before interest, taxes, depreciation and amortization. Adjusted EBITDA further excludes items of income or loss that we characterize as unrepresentative of our ongoing operations. Such items are excluded from net income or loss to determine Adjusted EBITDA. Management believes this measure provides investors meaningful insight into results from ongoing operations.

#### + OTHER NON-GAAP FINANCIAL MEASURES

Non-GAAP gross profit, research and development, net, selling, general and administrative, operating expenses, operating loss and total other income (expense), net, further excludes items of income or loss that we characterize as unrepresentative of our ongoing operations. Such items are excluded from the applicable GAAP financial measure. Management believes these non-GAAP measures provide investors meaningful insight into results from ongoing operations.



# ROCKET LAB U.S.A., INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

(unaudited; in thousands, except share and per share data)

	Three Months Ended September 30,					Nine Months Ended September 30,					
		2024		2023		2024		2023			
Revenues	\$	104,808	\$	67,661	\$	303,826	\$	184,601			
Cost of revenues		76,812		52,694		224,494		148,684			
Gross profit	· ·	27,996		14,967		79,332		35,917			
Operating expenses:											
Research and development, net		47,723		26,626		126,139		81,566			
Selling, general and administrative		32,172		27,200		91,445		84,386			
Total operating expenses		79,895		53,826		217,584		165,952			
Operating loss	·	(51,899)		(38,859)		(138,252)		(130,035)			
Other income (expense):											
Interest expense, net		(454)		(1,413)		(2,176)		(2,843)			
Loss on foreign exchange		(490)		(120)		(465)		(76)			
Other income, net		1,848		1,176		3,152		3,519			
Total other income (expense), net		904		(357)		511		600			
Loss before income taxes		(50,995)		(39,216)		(137,741)		(129,435)			
Provision for income taxes		(944)		(1,352)		(89)		(2,639)			
Net loss	\$	(51,939)	\$	(40,568)	\$	(137,830)	\$	(132,074)			
Net loss per share attributable to Rocket Lab USA, Inc.:											
Basic and diluted	\$	(0.10)	\$	(0.08)	\$	(0.28)	\$	(0.28)			
Weighted-average common shares outstanding:											
Basic and diluted		497,701,715		484,034,071		493,976,025		480,018,578			



# ROCKET LAB U.S.A., INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

# AS OF SEPTEMBER 30, 2024 AND DECEMBER 31, 2023

(unaudited; in thousands, except share and per share data)

(unaudited, in thousands, except share and per share	Septe	ember 30, 2024 inaudited)	December 31, 2023		
Assets					
Current assets:					
Cash and cash equivalents	\$	292,470	\$	162,518	
Marketable securities, current		149,919		82,255	
Accounts receivable, net		22,148		35,176	
Contract assets		49,461		12,951	
Inventories		114,435		107,857	
Prepaids and other current assets		67,066		66,949	
Assets held for sale		_		9,016	
Total current assets		695,499		476,722	
Non-current assets:					
Property, plant and equipment, net		170,983		145,409	
Intangible assets, net		61,582		68,094	
Goodwill		71,020		71,020	
Right-of-use assets - operating leases		53,985		59,401	
Right-of-use assets - finance leases		14,518		14,987	
Marketable securities, non-current		61,292		79,247	
Restricted cash		4,322		3,916	
Deferred income tax assets, net		1,419		3,501	
Other non-current assets		18,409		18,914	
Total assets	\$	1,153,029	\$	941,211	
Liabilities and Stockholders' Equity					
Current liabilities:					
Trade payables	\$	42,434	\$	29,303	
Accrued expenses		8,063		5,590	
Employee benefits payable		19,335		16,342	
Contract liabilities		167,129		139,338	
Current installments of long-term borrowings		11,758		17,764	
Other current liabilities		20,480		15,036	
Total current liabilities	<del></del>	269,199		223,373	
Non-current liabilities:		203,133		220,070	
Convertible senior notes, net		344,865		_	
Long-term borrowings, net, excluding current installments		46,915		87,587	
Non-current operating lease liabilities		51,906		56,099	
Non-current finance lease liabilities		15.042		15,238	
Deferred tax liabilities		726		426	
Other non-current liabilities		4,541		3,944	
Total liabilities		733,194		386,667	
COMMITMENTS AND CONTINGENCIES		733,194	_	380,007	
Stockholders' equity:					
Common stock, \$0.0001 par value; authorized shares: 2,500,000,000; issued and outstanding shares: 499,700,976 and 488,923,055 at September 30, 2024 and December 31, 2023, respectively		50		49	
Additional paid-in capital		1,178,828		1,176,484	
Accumulated deficit		(761,356)		(623,526)	
Accumulated other comprehensive income		2,313		1,537	
Total stockholders' equity		419,835		554,544	
Total liabilities and stockholders' equity	\$	1,153,029	\$	941,211	



## ROCKET LAB U.S.A., INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 (unaudited; in thousands)

	Fo	For the Nine Months Ended September 30			
		2024	2023		
CASH FLOWS FROM OPERATING ACTIVITIES:					
Net loss	\$	(137,830)	\$	(132,074)	
Adjustments to reconcile net loss to net cash used in operating activities:					
Depreciation and amortization		24,516		21,577	
Stock-based compensation expense		39,944		43,398	
(Gain) loss on disposal of assets		(2,356)		240	
Loss on extinguishment of long-term debt		1,330		_	
Amortization of debt issuance costs and discount		2,272		2,166	
Noncash lease expense		4,437		4,062	
Change in the fair value of contingent consideration		(218)		1,138	
Accretion of marketable securities purchased at a discount		(2,272)		(3,399)	
Deferred income taxes		2,310		644	
Changes in operating assets and liabilities:					
Accounts receivable, net		12,928		13,798	
Contract assets		(36,510)		(3,592)	
Inventories		(7,118)		(10,933)	
Prepaids and other current assets		1,951		(15,819)	
Other non-current assets		544		(10,712)	
Trade payables		13,853		12,026	
Accrued expenses		2,980		(2,187)	
Employee benefits payables		3,525		5,285	
Contract liabilities		27,791		25,450	
Other current liabilities		4,088		(4,632)	
Non-current lease liabilities		(4,321)		(3,316)	
Other non-current liabilities		1,653		230	
Net cash used in operating activities		(46,503)		(56,650)	
CASH FLOWS FROM INVESTING ACTIVITIES:		(40,303)		(50,050)	
Purchases of property, equipment and software		(45,539)		(44,293)	
Proceeds on disposal of assets, net		11,756		(++,2)3	
Cash paid for asset acquisition		11,730		(16,934)	
Purchases of marketable securities		(149,548)		(207,266)	
Maturities of marketable securities		102,930		219,340	
Net cash used in investing activities		(80,401)		(49,153)	
CASH FLOWS FROM FINANCING ACTIVITIES:		(60,401)		(49,133)	
		2,074		2,293	
Proceeds from the exercise of stock options		4,098		3,780	
Proceeds from Employee Stock Purchase Plan				12,390	
Proceeds from sale of employees restricted stock units to cover taxes		14,991		,	
Minimum tax withholding paid on behalf of employees for restricted stock units		(15,169)		(12,352)	
Payment of contingent consideration		(42.169)		(1,000)	
Purchase of capped calls related to issuance of convertible senior notes  Proceeds from issuance of convertible senior notes		(43,168)		_	
		355,000		_	
Repayments on Trinity Loan Agreement		(48,853)		_	
Payment of debt issuance costs		(12,205)		(240)	
Finance lease principal payments		(269)		(248)	
Net cash provided by financing activities		256,499		4,863	
Effect of exchange rate changes on cash and cash equivalents		763		(439)	
Net increase (decrease) in cash and cash equivalents and restricted cash		130,358		(101,379)	
Cash and cash equivalents, and restricted cash, beginning of period		166,434		245,871	
Cash and cash equivalents, and restricted cash, end of period	\$	296,792	\$	144,492	



## ROCKET LAB U.S.A., INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 (unaudited; in thousands)

The tables provided below reconcile the non-GAAP financial measures Adjusted EBITDA, Non-GAAP gross profit, Non-GAAP research and development, net, Non-GAAP selling, general and administrative, Non-GAAP operating expenses, Non-GAAP operating loss and Non-GAAP total other income (expense), net with the most directly comparable GAAP financial measures. See above for additional information on the use of these non-GAAP financial measures.

	Three Months Ended September 30,				Nine Months Ended September 30,			
		2024		2023		2024		2023
NET LOSS	\$	(51,939)	\$	(40,568)	\$	(137,830)	\$	(132,074)
Depreciation		4,793		4,237		14,513		11,463
Amortization		3,302		3,555		10,003		10,114
Stock-based compensation expense		12,896		14,098		39,944		43,398
Transaction costs		23		142		407		311
Interest expense, net		454		1,413		2,176		2,843
Change in fair value of contingent consideration		_		(462)		(218)		1,138
Performance reserve escrow		_		1,800		_		5,426
Provision for income taxes		944		1,352		89		2,639
Loss on foreign exchange		490		120		465		76
Accretion of marketable securities purchased at a discount		(666)		(1,447)		(2,272)		(3,601)
(Gain) loss on disposal of assets		(1,164)		213		(2,356)		240
Employee retention credit		_		_		_		(3,841)
Loss on extinguishment of debt		_		_		1,330		_
ADJUSTED EBITDA	\$	(30,867)	\$	(15,547)	\$	(73,749)	\$	(61,868)



	Three Months Ended September 30,			Nine Months Ended September 30,				
		2024		2023		2024		2023
GAAP Gross profit	\$	27,996	\$	14,967	\$	79,332	\$	35,917
Stock-based compensation		3,029		3,182		10,205		10,325
Amortization of purchased intangibles and favorable lease		1,763		1,710		5,247		5,129
Performance reserve escrow		_		76		_		209
Employee retention credit		_		_		_		(2,130)
Non-GAAP Gross profit	\$	32,788	\$	19,935	\$	94,784	\$	49,450
Non-GAAP Gross margin		31.3 %		29.5 %		31.2 %		26.8 %
GAAP Research and development, net	\$	47,723	\$	26,626	\$	126,139	\$	81,566
Stock-based compensation		(4,626)		(6,219)		(13,660)		(17,893)
Amortization of purchased intangibles and favorable lease		(302)		(315)		(686)		(333)
Employee retention credit		_		_		_		631
Non-GAAP Research and development, net	\$	42,795	\$	20,092	\$	111,793	\$	63,971
GAAP Selling, general and administrative	\$	32,172	\$	27,200	\$	91,445	\$	84,386
Stock-based compensation		(5,241)		(4,697)		(16,079)		(15,180)
Amortization of purchased intangibles and favorable lease		(960)		(1,378)		(3,274)		(4,207)
Transaction costs		(23)		(142)		(407)		(311)
Performance reserve escrow		_		(1,724)		_		(5,217)
Change in fair value of contingent consideration		_		462		218		(1,138)
Employee retention credit		_		_		_		1,080
Non-GAAP Selling, general and administrative	\$	25,948	\$	19,721	\$	71,903	\$	59,413
GAAP Operating expenses	\$	79,895	\$	53,826	\$	217,584	\$	165,952
Stock-based compensation		(9,867)		(10,916)		(29,739)		(33,073)
Amortization of purchased intangibles and favorable lease		(1,262)		(1,693)		(3,960)		(4,540)
Transaction costs		(23)		(142)		(407)		(311)
Performance reserve escrow		_		(1,724)		_		(5,217)
Change in fair value of contingent consideration		_		462		218		(1,138)
Employee retention credit		_		_		_		1,711
Non-GAAP Operating expenses	\$	68,743	\$	39,813	\$	183,696	\$	123,384
GAAP Operating loss	\$	(51,899)	\$	(38,859)	\$	(138,252)	\$	(130,035)
Total non-GAAP adjustments		15,944		18,981		49,340		56,101
Non-GAAP Operating loss	\$	(35,955)	\$	(19,878)	\$	(88,912)	\$	(73,934)
GAAP Total other income (expense), net	\$	904	\$	(357)	\$	511	\$	600
Loss on foreign exchange		490		120		465		76
(Gain) loss on disposal of assets		(1,164)		213		(2,356)		240
Loss on extinguishment of debt				_		1,330		_
Non-GAAP Total other income (expense), net	\$	230	\$	(24)	\$	(50)	\$	916
	_							